We provide a full range of legal services to the investment community including the establishment and marketing of funds,
the making of investments and structuring of deals and acquisition finance and buy-outs. We also represent clients in all
phases of venture capital and private equity activities including seed capital, first and later rounds of funding, debt financing,
trade sales, initial public offerings and secondary sales. Consequently, the team has developed a thorough understanding
of the issues and concerns of both companies seeking funding and investors.
We have particular strength in relation to private equity and venture capital for companies in the healthcare / life sciences,
technology, media and telecommunications sectors and these companies form a core part of our client base.
We also have significant strength in cross-border transactions. Our work is usually international in nature and U.S. and
UK qualified lawyers in the European practice work closely with attorneys from our network of 17 offices worldwide, providing
a broad range of international capabilities and services to our clients.
Recent Transactions
- Apax Partners. Acting as U.S. counsel for funds advised by Apax Partners in relation to an $11 million investment in global financial software
company Iris Financial Engineering.
- De Novo Pharmaceuticals. Representing De Novo Pharmaceuticals in a venture capital financing.
- Derms Development Limited. Representing Derms Development Limited in the £4 million financing and acquisition of Crawfords.
- Indigo Software Group, Inc. Advising on a $4.5 million funding for Indigo Software Group, Inc., a software developer producing Internet communications
solutions for a broad range of services providers from ISP to next generation telecoms operators.
- Intercytex. Advising Intercytex, the cell therapy company developing products for the advanced woundcare and aesthetic medicine markets,
on a £12 million private equity financing from its existing shareholders: Avlar BioVentures, Merlin Biosciences, 3i, Cambridge
Gateway Partnership, NIF Ventures and Scottish Equity Partners.
- IWP International plc. Acting as English counsel for IWP International in a €134 million leveraged buy-out of its household products division.
- NDTV Networks plc. Representing NDTV Networks plc, a subsidiary of New Delhi Television Ltd (India's largest private producer of news, current
affairs and entertainment television), in completing an investment round of US$20 million.
- Netronome Systems, Inc. Acting for Spinner Asset Management and Top Technology on a Series B financing for Netronome.
- Pathway Capital Management. Representing Pathway and one other keystone investor in their investment in Montagu Private Equity's fourth fund.
- Speciality European Pharma. Advising Speciality European Pharma on a €15 million Series A round in which Advent Venture Partners was the sole investor
and on the subsequent acquisition of Proreo Pharma (Liestal, Switzerland) as well as worldwide rights to prostate cancer drug
Plenaxis abarelix from Praecis. Advent Ventures has formed Speciality European Pharma to acquire pharmaceutical prescription
products for development and marketing in Europe.
